Dr. Robin Jones on Olaratumab and Doxorubicin in Patients with Soft Tissue Sarcoma

ANNOUNCE: doxorubicin + olaratumab in advanced soft tissue sarcomasПодробнее

Early Data With Olaratumab in Soft Tissue SarcomaПодробнее

Toxicity of Olaratumab and DoxorubicinПодробнее

Dr. Tap on Olaratumab in Patients With Soft Tissue SarcomaПодробнее

Appropriate Patients for Olaratumab + DoxorubicinПодробнее

Olaratumab + Doxorubicin for Metastatic Soft-Tissue SarcomaПодробнее

Olaratumab Plus Doxorubicin in Advanced Soft Tissue SarcomaПодробнее

SPAEN Webinar Experiences with olaratumab in soft tissue sarcomas with Robin Jones, UK 201810021606Подробнее

Soft Tissue Sarcoma: Role of OlaratumabПодробнее

Overall Survival with OlaratumabПодробнее

Overall Survival with OlaratumabПодробнее

How has the trabectedin extended access program benefited sarcoma patients?Подробнее

The current state of drug development against sarcomasПодробнее

Trustedoctor - discussion with Dr. Robin Jones from the Royal Marsden NHS TrustПодробнее

Evofosfamide Versus Ifosfamide Patient Selection in Soft Tissue SarcomaПодробнее

The Role of Olaratumab in SarcomaПодробнее

Dr. Tap on Improved Overall Survival With Olaratumab/Doxorubicin CombinationПодробнее

Dr. Philip on Olaratumab for Soft Tissue SarcomaПодробнее

The Impact and Long-Term Potential of Olaratumab in Soft Tissue SarcomaПодробнее